US 11,963,941 B2
Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer
Alessio Nencioni, Genoa (IT); Alberto Ballestrero, Genoa (IT); Patrizio Odetti, Genoa (IT); Fiammetta Monacelli, Genoa (IT); Irene Caffa, Alassio (IT); and Valter Longo, Culver City, CA (US)
Assigned to UNIVERSITA' DEGLI STUDI DI, Genoa (IT); and L-NUTRA INC., Culver City, CA (US)
Appl. No. 16/075,187
Filed by UNIVERSITA' DEGLI STUDI DI GENOVA, Genoa (IT); and L-NUTRA INC., Culver City, CA (US)
PCT Filed Feb. 14, 2017, PCT No. PCT/EP2017/053209
§ 371(c)(1), (2) Date Aug. 3, 2018,
PCT Pub. No. WO2017/140641, PCT Pub. Date Aug. 24, 2017.
Claims priority of application No. 102016000017036 (IT), filed on Feb. 18, 2016.
Prior Publication US 2019/0038591 A1, Feb. 7, 2019
Int. Cl. A61K 31/337 (2006.01); A61K 31/138 (2006.01); A61K 31/565 (2006.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/337 (2013.01) [A61K 31/138 (2013.01); A61K 31/565 (2013.01); A61K 31/704 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 11 Claims
 
1. A method of treating estrogen-responsive breast cancer (BC) in a human patient, which method comprises subjecting said patient to reduced caloric intake for a period of 24-190 hours while said patient is being treated with a compound having antiestrogenic activity, wherein said compound is a SERM and is selected among the group consisting of tamoxifen, raloxifene, toremifene, lasofoxifene, ospemifene, arzoxifene and bazedoxifene.